Encouraging results from the CureParkinsons supported Phase II clinical trial of the GLP-1R agonist Liraglutide

There were 37 randomly assigned to Liraglutide & 18 on placebo (2:1); At 54 weeks, non-motor symptoms scale scores had improved by 6.6 points in the liraglutide group & worsened by 6.5 points in the placebo group; MDS-UPDRS III (change from baseline) = not significantly different

Secondary outcome analysis revealed a significant improvement in MDS-UPDRS II scores in the treatment group (-4.1 points, p=0.001 - curiously, self assessed motor scores were significantly better)

Drug was safe & well tolerated

Results add to accumulating GLP-1R data pile

cureparkinsons.org.uk/2022/...

twitter.com/ScienceofPD/sta...

[park_bear]

This was a poster presentation reported on here:

aan.com/MSA/Public/Events/D...

"At 54 weeks, NMSS scores had improved by 6.6 points in the liraglutide group and worsened by 6.5 points in the placebo group, a 13.1 point adjusted mean difference (p=0.07)."

NMSS = nonmotor symptom score. Available here:

movementdisorders.org/MDS-F...

Possible scores range from 0 to 360.

" MDS-UPDRS part III and MDRS-2 score changes from baseline did not significantly differ between active and placebo. Secondary outcome analysis revealed a significant improvement in MDS-UPDRS part-II scores in the treatment group (-4.1 points, p=0.001)."

MDS-UPDRS part-II: Motor Aspects of Experiences of Daily Living (M-EDL). Maximum score 52.

"Injection site reactions and gastrointestinal symptoms were common AEs. Eleven serious AEs were reported, none of which related to the study intervention."

I do wonder what the serious adverse events were though.

[Parkinsonjisung in reply to park_bear]

This is super news. More evidence that glp1 type drugs have an effect on parkinsons

[House2 in reply to Parkinsonjisung]

In summary, myricetin was determined to be a small-molecule chemical agent that activates GLP-1R, and its physiochemical properties suggest that myricetin could be the first natural agonist of GLP-1R that can be orally administered.

faseb.onlinelibrary.wiley.c....

[Lwpd in reply to park_bear]

" MDS-UPDRS part III and MDRS-2 score changes from baseline did not significantly differ between active and placebo. Secondary outcome analysis revealed a significant improvement in MDS-UPDRS part-II scores in the treatment group (-4.1 points, p=0.001)."

Can someone explain this to me please?

As I read it, the first part of the sentence says it didn’t make a difference to motor aspects of the disease. Then the second part says it did? What is secondary outcome analysis and why does that differ from the baseline scores?

[park_bear in reply to Lwpd]

"MDRS-2" is Mattis Dementia Rating Scale. MDS-UPDRS part II and MDS-UPDRS part III refer to different types of motor symptoms. Part II result was stat sig, whereas part III was not.

Baseline refers to beginning scores at the start of the trial, outcome refers to scores at the end of the trial.

[kevowpd in reply to park_bear]

Think part ii is a survey regarding daily living activities and part iii is an in person examination.

[park_bear in reply to kevowpd]

Yep. Available here:

movementdisorders.org/MDS-F...

Part II: Motor Aspects of Experiences of Daily Living (M-EDL)

Part III: Motor Examination

[Lwpd in reply to park_bear]

Thanks. The cure Parkinson’s site says it is encouraging with regards to non motor symptoms and quality of life..

It was more the secondary outcome analysis I didn’t understand, but I read the clinical trials paper and get a better feel for it now. Promising results coming out of many trials now using GLP-1 agonists.

[jeffmayer]

Could someone translate into english for us mere mortals

[Parkinsonjisung in reply to jeffmayer]

It's a very similar drug to exenatide which is phase 3. It's results further add to the theory that exenatide may slow or even stop the progression of parkinson at least in some people. It's a lot of ifs and maybes but it's very positive news.